Alto Neuroscience $ANRO
Shortfinder β’ Published December 30, 2025 β’ ML Model Identifies #1 Risk Stock
CORE INVESTMENT THESIS
ANRO faces acute supply risk as 8.4 million PIPE shares become freely tradeable with investors sitting on 200% unrealized gains.
Three converging factors create this setup: PIPE profit-taking pressure, toxic investor profiles with negative historical returns, and ANRO's own 22% decline following its last shelf effectiveness. Shortfinder's ML model assigns the highest risk score in their 800+ stock universe.
COMPANY OVERVIEW
KEY FINANCIAL METRICS
October 2025 private placement
As of report date
PIPE investors' current profit
At 100% volume capture
ML MODEL PREDICTIONS (v1.1.0)
Composite Risk Score: 0.0847 β Highest in 800+ stock universe
| Horizon | Decline Probability | Expected Magnitude |
|---|---|---|
| 1 Day | 51.8% | -3.2% |
| 5 Day | 54.2% | -6.8% |
| 20 Day | 48.7% | -9.1% |
HISTORICAL RETURNS AFTER DILUTION EVENTS
PIPE TRANSACTION STRUCTURE ($50M)
Total: 8,454,514 shares
Float Impact: 38% of pre-deal float
KEY PLAYERS β PIPE INVESTORS
TRADE STRUCTURE
Entry Zone
$17.00β$18.00
Price Target 1
$14.20 (β20%)
Price Target 2
$11.50 (β35%)
Stop-Loss
$21.00 (+18%)
Risk/Reward
1:1.5 to 1:2
Time Horizon
5β20 Days